Separately, Zacks Investment Research downgraded BioSig Technologies from a “hold” rating to a “sell” rating in a research report on Thursday, June 6th.
BioSig Technologies stock opened at $7.01 on Wednesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.52 and a current ratio of 7.52. BioSig Technologies has a one year low of $3.50 and a one year high of $9.97. The business has a 50 day simple moving average of $7.33 and a 200 day simple moving average of $7.06.
In related news, CEO Kenneth L. Londoner bought 4,650 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The stock was acquired at an average price of $6.29 per share, for a total transaction of $29,248.50. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. 26.70% of the stock is owned by company insiders.
Hedge funds have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN increased its stake in shares of BioSig Technologies by 376.1% in the 2nd quarter. Wells Fargo & Company MN now owns 2,871 shares of the company’s stock valued at $27,000 after buying an additional 2,268 shares during the period. Steward Partners Investment Advisory LLC acquired a new stake in shares of BioSig Technologies during the second quarter worth $32,000. US Bancorp DE bought a new position in BioSig Technologies during the second quarter worth about $38,000. Strs Ohio bought a new position in BioSig Technologies during the second quarter worth about $39,000. Finally, JPMorgan Chase & Co. lifted its holdings in BioSig Technologies by 760.6% during the second quarter. JPMorgan Chase & Co. now owns 4,303 shares of the company’s stock worth $41,000 after acquiring an additional 3,803 shares in the last quarter. 12.01% of the stock is owned by hedge funds and other institutional investors.
About BioSig Technologies
BioSig Technologies, Inc, a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. Its product is PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and catheter ablation procedures.
Recommended Story: Growth Stocks
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for BioSig Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BioSig Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.